查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566764

脊椎生技药品市场：按产品、最终用户：2024-2033 年全球机会分析与产业预测

Spine Biologics Market By Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix) , By End User (Hospitals, Outpatient Facilities) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

脊椎生技药品市场

2023年脊椎生技药品市值为30.5亿美元，预计2035年将达55.5亿美元，2024年至2035年复合年增长率为5.29%。

脊椎生技药品由促进脊椎融合、促进癒合和治疗多种脊椎疾病的材料组成。这种材料含有生长因子、干细胞和骨移植物，有助于身体的自然癒合过程。骨移植是新骨生长所需的支架。骨移植包括来自患者自身的自体移植物和来自捐赠者的异体移植物。干细胞是能够产生具有完整功能的新细胞的特殊细胞，骨生成激素（BMP）等生长因子在刺激细胞再生和骨骼修復方面发挥作用。脊椎生技药品在连接两个或更多脊椎骨的脊椎融合手术中广泛使用。

脊椎疾病的盛行率不断增加，特别是在快速增长的老年人口中，是脊椎生技药品市场的主要驱动因素。此外，随着微创手术趋势的日益发展，对在脊椎手术过程中最大限度地减少侵入性并促进癒合的脊椎生技药品的需求激增。近年来，利用积层製造开发移植骨替代物已成为市场的新兴趋势。与骨移植物相比，这些替代品具有相当的功效和更高的安全性，骨移植物有可能被生物体排斥。

然而，脊椎生技药品的开发过程复杂且成本高昂，限制了市场的发展。此外，无效的报销政策导致脊椎手术保险不足，阻碍了昂贵的治疗并限制了市场成长。相反，脊椎损伤的数量不断增加，预计未来将推动脊椎生技药品的需求。美国国家医学图书馆最近发表的一篇论文显示，美国每年新发脊髓损伤的38%是由于机动车事故造成的，而跌倒是脊髓损伤的第二常见原因，占30%。的%。

按部门审查

脊椎生技药品市场分为产品、最终用户和地区。根据产品，它分为脊椎同种异体移植物、移植骨替代物和基于细胞的基质。依最终使用者分为医院和门诊设施。从区域来看，分析包括北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

从产品来看，脊椎植入物细分市场将在 2023 年占据主导地位。

按最终用户划分，医院细分市场在 2023 年将占据较高市场份额。

按地区划分，预计到 2035 年，北美地区的收益将最高。

该报告可以定制。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章脊椎生技药品市场：副产品

  • 市场概况
  • 脊椎移植物
  • 移植骨替代物
  • 基于细胞的矩阵

第五章脊椎生技药品市场：依最终用户分类

  • 市场概况
  • 医院
  • 门诊病人设施

第六章脊椎生技药品市场：依地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国脊椎生技药品市场
    • 加拿大脊椎生技药品市场
    • 墨西哥脊椎生技药品市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国脊椎生技药品市场
    • 法国脊椎生技药品市场
    • 英国脊椎生技药品市场
    • 义大利脊椎生技药品市场
    • 西班牙脊椎生技药品市场
    • 其他欧洲脊椎生技药品市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本脊椎生技药品市场
    • 中国脊椎生技药品市场
    • 澳洲脊椎生技药品市场
    • 印度脊椎生技药品市场
    • 韩国脊椎生技药品市场
    • 其他亚太脊椎生技药品市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西脊椎生技药品市场
    • 沙乌地阿拉伯脊椎生技药品市场
    • 南非脊椎生技药品市场
    • 其他拉丁美洲/中东/非洲脊椎生技药品市场

第七章 竞争状况

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第八章 公司简介

  • Stryker Corporation
  • NuVasive, Inc.
  • Orthofix
  • Johnson And Johnson
  • Exactech, Inc
  • Zimmer Biomet Holding, Inc.
  • Arthrex, Inc.
  • Medtronic Plc
  • Organogenesis Inc
  • Kuros Biosciences
简介目录
Product Code: A01625

Spine Biologics Market

The spine biologics market was valued at $3.05 billion in 2023 and is estimated to reach $5.55 billion by 2035, exhibiting a CAGR of 5.29% from 2024 to 2035.

Spine biologics comprises of materials that enhance spinal fusion, promote healing, and treat several spinal disorders. The materials involve growth factors, stem cells, and bone grafts, which help in the natural healing processes of the body. Bone grafts are the scaffolds required for new bone growth. They include autografts, which belong to patient's own body, and allografts, which are derived from a donor. Stem cells are a special form of cells that have the ability to generate new cells with complete functionalities and growth factors, such as bone morphogenetic proteins (BMPs), play role in stimulating the cells for regeneration and bone repair. The usage of spine biologics is widespread in spinal fusion surgeries, which involve the joining of two or more vertebrae.

Increase in the prevalence of spinal disorders, particularly in the exponentially growing geriatric population, is a key driver of the spine biologics market. In addition, with rising inclination toward minimally invasive procedures, the demand for spine biologics is surging as they facilitate minimal invasion during spinal surgeries and promote healing. In recent times, the use of additive manufacturing for the development of bone graft substitute is an emerging trend in the market. These substitutes offer equivalent efficacy and improved safety when compared to bone grafts, which hold the potential for rejection by the body.

However, the development of spine biologics is a complex procedure with high expenses, hence restraining the development of the market. Furthermore, the ineffective reimbursement policies that do not offer adequate cover for spinal surgeries deter individuals from undergoing expensive treatments, hence limiting the market growth. On the contrary, the consistently rising numbers of spinal injuries are anticipated to propel the demand for spine biologics in the future. The National Library of Medicine recently published an article which reported that every year 38% of new spinal cord injuries occur due to motor vehicular crashes in the U.S. falling is the second most prevalent reason for spinal injuries, accounting for 30% of the total count.

Segment Review

The spine biologics market is segmented into product, end user, and region. By product, the market is divided into spinal allografts, bone graft substitutes, and cell-based matrix. As per end user, it is bifurcated into hospitals and outpatient facilities. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By product, the spinal allografts segment dominated the market in 2023.

As per end user, the hospital segment acquired a high stake in the market in 2023.

Region wise, North America is projected to be the highest revenue generator by 2035.

Competition Analysis

The major players operating in the spine biologics market are Stryker, NuVasive, Inc., Orthofix, Johnson & Johnson, Exactech, Inc., Zimmer Biomet. Arthrex, Inc., Medtronic Plc, Organogenesis Inc., and Kuros Biosciences. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product

  • Spinal Allografts
  • Bone Graft Substitutes
  • Cell-Based Matrix

By End User

  • Hospitals
  • Outpatient Facilities

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Stryker Corporation
    • NuVasive, Inc.
    • orthofix
    • Johnson & Johnson
    • Exactech, Inc
    • Zimmer Biomet Holding, Inc.
    • Arthrex, Inc.
    • Medtronic plc
    • Organogenesis Inc
    • Kuros Biosciences

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: SPINE BIOLOGICS MARKET, BY PRODUCT

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product
  • 4.2. Spinal Allografts
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Bone Graft Substitutes
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Cell-Based Matrix
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: SPINE BIOLOGICS MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospitals
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Outpatient Facilities
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: SPINE BIOLOGICS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Product
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Spine Biologics Market
      • 6.2.5.1. Market Size and Forecast, By Product
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Spine Biologics Market
      • 6.2.6.1. Market Size and Forecast, By Product
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Spine Biologics Market
      • 6.2.7.1. Market Size and Forecast, By Product
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Product
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Spine Biologics Market
      • 6.3.5.1. Market Size and Forecast, By Product
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. France Spine Biologics Market
      • 6.3.6.1. Market Size and Forecast, By Product
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. UK Spine Biologics Market
      • 6.3.7.1. Market Size and Forecast, By Product
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Italy Spine Biologics Market
      • 6.3.8.1. Market Size and Forecast, By Product
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. Spain Spine Biologics Market
      • 6.3.9.1. Market Size and Forecast, By Product
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Spine Biologics Market
      • 6.3.10.1. Market Size and Forecast, By Product
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Product
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Spine Biologics Market
      • 6.4.5.1. Market Size and Forecast, By Product
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. China Spine Biologics Market
      • 6.4.6.1. Market Size and Forecast, By Product
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. Australia Spine Biologics Market
      • 6.4.7.1. Market Size and Forecast, By Product
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. India Spine Biologics Market
      • 6.4.8.1. Market Size and Forecast, By Product
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. South Korea Spine Biologics Market
      • 6.4.9.1. Market Size and Forecast, By Product
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Spine Biologics Market
      • 6.4.10.1. Market Size and Forecast, By Product
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Product
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Spine Biologics Market
      • 6.5.5.1. Market Size and Forecast, By Product
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. Saudi Arabia Spine Biologics Market
      • 6.5.6.1. Market Size and Forecast, By Product
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. South Africa Spine Biologics Market
      • 6.5.7.1. Market Size and Forecast, By Product
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Spine Biologics Market
      • 6.5.8.1. Market Size and Forecast, By Product
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Stryker Corporation
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. NuVasive, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Orthofix
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Johnson And Johnson
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Exactech, Inc
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Zimmer Biomet Holding, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Arthrex, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Medtronic Plc
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Organogenesis Inc
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Kuros Biosciences
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments